Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients

Cancer Immunology, Immunotherapy

Volumn 65, Issue 1, 2016, Pages 37-45

  Saavedra, Danay ^a   García, Beatriz ^a   Lorenzo Luaces, Patricia ^a   González, Amnely ^a   Popa, Xitlally ^a   Fuentes, Karla P ^a   Mazorra, Zaima ^a   Crombet, Tania ^a   Neninger, Elia ^b   Lage, Agustin ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b HOSPITAL CLINICOQUIRÚRGICO HERMANOS AMEIJEIRAS   (Cuba)

Author keywords

Cancer vaccine; Immunosenescence; Immunosenescence markers; Non small cell lung cancer

Indexed keywords

BIOLOGICAL MARKER;

FEMALE; HUMAN; IMMUNOLOGY; IMMUNOSENESCENCE; LUNG TUMOR; MALE; MORTALITY; PATHOLOGY; PHYSIOLOGY; SURVIVAL ANALYSIS;

BIOMARKERS; FEMALE; HUMANS; IMMUNOSENESCENCE; LUNG NEOPLASMS; MALE; SURVIVAL ANALYSIS;

EID: 84953369432     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1773-6     Document Type: Article

References (32)

1. Fulop T, Larbi A, Kotb R, Pawelec G (2013) Immunology of aging and cancer development. Interdiscip Top Gerontol 38:38–48. doi:10.1159/000343599
2. Fulop T, Larbi A, Kotb R, de Angelis F, Pawelec G (2011) Aging, immunity, and cancer. Discov Med 11:537–550
3. Lang PO, Govind S, Aspinall R (2013) Reversing T cell immunosenescence: why, who, and how. Age 35:609–620. doi:10.1007/s11357-012-9393-y
4. Pawelec G (2014) Immunosenenescence: role of cytomegalovirus. Exp Gerontol 54:1–5. doi:10.1016/j.exger.2013.11.010
5. Pawelec G (2012) Hallmarks of human “immunosenescence”: adaptation or dysregulation? Immun Ageing 9:15. doi:10.1186/1742-4933-9-15
6. Falci C, Gianesin K, Sergi G, Giunco S, De Ronch I, Valpione S et al (2013) Immune senescence and cancer in elderly patients: results from an exploratory study. Exp Gerontol 48:1436–1442. doi:10.1016/j.exger.2013.09.011
7. Mazzola P, Radhi S, Mirandola L, Annoni G, Jenkins M, Cobos E, Chiriva-Internati M (2012) Aging, cancer, and cancer vaccines. Immun Ageing 9:4. doi:10.1186/1742-4933-9-4
8. Chen IH, Lai YL, Wu CL, Chang YF, Chu CC, Tsai IF, Sun FJ, Lu YT (2010) Immune impairment in patients with terminal cancers: influence of cancer treatments and cytomegalovirus infection. Cancer Immunol Immunother 59:323–334. doi:10.1007/s00262-009-0753-0
9. Verdecia BG, Hernández DS, Lorenzo-Luaces P, Alvarez TDJB, Rupalé IL, Herrera ZM, Ramos TC, Dávila AL (2013) Immunosenescence and gender: a study in healthy Cubans. Immun Ageing 10(1):16. doi:10.1186/1742-4933-10-16
10. Gonzalez G, Diaz-Miqueli A, Crombet T, Raez LE, Lage A (2013) Current algorithm for treatment of advanced NSCLC patients: How to include active immunotherapy? J Cancer Ther 4(8A):59–75. doi:10.4236/jct.2013.48A010
11. Neninger Vinageras E, de la Torre A, Osorio Rodríguez M, Catalá Ferrer M, Bravo I, Mendoza del Pino M, Abreu Abreu D, Acosta Brooks S, Rives R, del Castillo Carrillo C, González Dueñas M, Viada C, García Verdecia B, Crombet Ramos T, González Marinello G, Lage Dávila A (2008) Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 26(9):1452–1458. doi:10.1200/JCO.2007.11.5980
12. Fulop T, Larbi A, Witkowski JM, Kotb R, Hirokawa K, Pawelec G (2013) Immunosenescence and cancer. Crit Rev Oncog 18:489–513
13. Libri V, Azevedo RI, Jackson SE, Di Mitri D, Lachmann R, Fuhrmann S, Vukmanovic-Stejic M, Yong K, Battistini L, Kern F, Soares MV, Akbar AN (2011) Cytomegalovirus infection induces the accumulation of short-lived, multifunctional CD4 + CD45RA + CD27+ T cells: the potential involvement of interleukin-7 in this process. Immunology 132:326–339. doi:10.1111/j.1365-2567.2010.03386.x
14. Appay V, Sauce D, Prelog M (2010) The role of the thymus in immunosenescence: lessons from the study of thymectomized individuals. Aging 2:78–81
15. Appay V, van Lier RA, Sallusto F, Roederer M (2008) Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 73:975–983. doi:10.1002/cyto.a.20643
16. Larbi A, Fulop T (2014) From “truly naive” to “exhausted senescent” T cells: when markers predict functionality. Cytom A 85:25–35. doi:10.1002/cyto.a.22351
17. Garcia B, Neninger E, de la Torre A, Leonard I, Martinez R, Viada C, Gonzalez G, Mazorra Z, Lage A, Crombet T (2008) Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 14:840–846. doi:10.1158/1078-0432.CCR-07-1050
18. Fulop T, Kotb R, Fortin CF, Pawelec G, de Angelis F, Larbi A (2010) Potential role of immunosenescence in cancer development. Ann NY Acad Sci 1197:158–165. doi:10.1111/j.1749-6632.2009.05370.x
19. Gravekamp C (2011) The impact of aging on cancer vaccination. Curr Opin Immunol 23:555–560. doi:10.1016/j.coi.2011.05.003
20. Pritz T, Weinberger B, Grubeck-Loebenstein B (2014) The aging bone marrow and its impact on immune responses in old age. Immunol Lett 162(1 Pt B):310–315. doi:10.1016/j.imlet.2014.06.016
21. Fulop T, Montgomery RR (2014) Editorial overview: immune senescence: known knowns and unknown unknowns. Curr Opin Immunol 29:7–9. doi:10.1016/j.coi.2014.06.005
22. Olsson J, Wikby A, Johansson B, Lofgren S, Nilsson BO, Ferguson FG (2000) Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev 121:187–201
23. Strindhall J, Skog M, Ernerudh J, Bengner M, Lofgren S, Matussek A, Nilsson BO, Wikby A (2013) The inverted CD4/CD8 ratio and associated parameters in 66-year-old individuals: the Swedish HEXA immune study. Age 35:985–991. doi:10.1007/s11357-012-9400-3
24. Whiteside TL (2013) Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 41:245–251. doi:10.1042/BST20120265
25. Akbar AN, Henson SM (2011) Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat Rev Immunol 11:289–295. doi:10.1038/nri2959
26. Derhovanessian E, Maier AB, Hahnel K, Beck R, de Craen AJ, Slagboom EP, Westendorp RG, Pawelec G (2011) Infection with cytomegalovirus but not herpes simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in humans. J Gen Virol 92:2746–2756. doi:10.1099/vir.0.036004-0
27. McElhaney JE, Effros RB (2009) Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol 21:418–424. doi:10.1016/j.coi.2009.05.023
28. Pallis AG, Hatse S, Brouwers B, Pawelec G, Falandry C, Wedding U, Lago LD, Repetto L, Ring A, Wildiers H (2014) Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging? J Geriatr Oncol 5:204–218. doi:10.1016/j.jgo.2013.09.001
29. Chang S, Kohrt H, Maecker HT (2014) Monitoring the immune competence of cancer patients to predict outcome. Cancer Immunol Immunother 63:713–719. doi:10.1007/s00262-014-1521-3
30. Gustafson MP, Lin Y, LaPlant B, Liwski CJ, Maas ML, League SC, Bauer PR, Abraham RS, Tollefson MK, Kwon ED, Gastineau DA, Dietz AB (2013) Immune monitoring using the predictive power of immune profiles. J Immunother Cancer 1:7. doi:10.1186/2051-1426-1-7
31. Kelloff GJ, Sigman CC (2012) Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov 11:201–214. doi:10.1038/nrd3651
32. Lima L, Oliveira D, Ferreira JA, Tavares A, Cruz R, Medeiros R, Santos L (2015) The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guérin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population. BJU Int 116(5):753–63. doi:10.1111/bju.12844